Adagene is a global, clinical-stage immunotherapy company listed on Nasdaq. Their mission is to revolutionize cancer treatment by redefining the discovery and design of antibodies. With their cutting-edge platform, Adagene is at the forefront of developing therapeutic antibodies that open new horizons in healthcare.

Their technology is built upon a deep understanding of protein folding and molecular motion, enabling them to create dynamic and adaptive engagement with targeted proteins. Adagene's platform consists of unique, multi-purpose antibody technologies and a robust pipeline of novel assets with innovative mechanisms of action. They employ precision engineering to identify and select antibody candidates that have the highest potential for achieving desired biological effects.

As a result, Adagene is making significant strides in the field of immunotherapy, offering hope to patients worldwide. Discover more about their groundbreaking research and development on their website